Issue link: https://www.e-digitaleditions.com/i/1526741
10 BioPharm International ® Emerging Therapies eBook September 2024 www.biopharminternational.com Cell Line Development Traditional methods such as enzyme-linked immu- nosorbent assays (ELISAs) have limitations in sensitiv- ity, specificity, and coverage, which can delay the iden- tification of inconsistencies. Identifying and mitigating data inconsistencies early in the development process is paramount during CLD to ensure the stability and effi- cacy of the final biotherapeutic product. The integration of CE- and MS-based technologies offers a robust solu- tion that can significantly enhance the detection of data inconsistencies, facilitating the development of stable cell lines for bioproduction. CE provides rapid assays that can assess key factors af- fecting final product stability, such as charge and glycan profiles, while MS offers precise information about key factors affecting product quality, such as molecular mod- ifications and their localization and protein structure. Ensuring product stability During the manufacturing of mAbs and other complex therapeutics, heterogeneity can arise from enzymatic cleavage and PTMs. Ensuring stability and consistency in therapeutic protein production necessitates meticu- lous monitoring and control of PTMs and genetic mu- tations. Moreover, the early detection and characteriza- tion of these PTMs during CLD can prevent costly and time-consuming issues later in the production process. The final therapeutic product can be affected by changes induced by various cell processing and growth conditions, which, therefore, must be comprehensively understood. Alterations in titer, cell culture media, and other process conditions can induce PTMs that affect the stability and activity of the final protein product. Therefore, gathering comprehensive information about key quality attributes, including PTMs, is crucial to un- derstanding the stability of proteins produced by cell lines. This comprehensive understanding can aid in selecting more resilient cell lines or identifying prob- lematic areas that can be addressed. Monitoring charge variants and PTMs At the intact level, monitoring PTMs can be accom- plished by charge variant analysis. P TMs induce shifts in the isoelectric point (pI) of a molecule, mak- ing charge heterogeneity a standard CQA monitored throughout the development pipeline. As therapeutic molecules become more complex, charge heterogene- ity increases, complicating monitoring efforts. CE-based workflows offer rapid and straightforward assessments of key factors affecting stability, such as charge heterogeneity, and glycan profile. High-through- put assays enable rapid narrowing down of potential clones, expediting the development pipeline. MS pro- vides precise information about PTM localization and protein structure, through assays such as subunit anal- ysis and peptide mapping. However, traditional peptide mapping can be time-consuming and typically unsuit- able for early clone selection. Integrating CE and MS for enhanced stability The direct integration of CE and MS technologies can elucidate ob- served pI shifts without requiring extensive fractionation or peptide mapping. Technologies such as im- aged capillary isoelectric focusing (icIEF) with ultraviolet (UV) detec- tion combined with MS (icIEF–UV/ MS) can provide high-resolution separation based on pI and mass id e nt i f ic a t ion , e n a bl i n g c om- prehensive cha rac ter i zat ion of protein charge variants in intact proteins, and aid in identif ying unexpected PTMs. These systems provide critical information about proteoform identity at the intact protein level, contributing to risk re- duction in CLD and the development pipeline overall (see Figure 1) (1–4). They facilitate informed decisions on clonal selection and bioreactor condition optimization earlier in the process. FIGURE 1. Overlay of imaged capillary isoelectric focusing with ultraviolet (icIEF–UV) profiles demonstrating separated charge variants for monoclonal antibodies (mAbs): bevacizumab (blue), infliximab (red), and trastuzumab (black), from icIEF– UV with mass spectrometry data (4). ALL FIGURES ARE COURTESY OF THE AUTHORS